Anti-inflammatory use during surgery could improve cancer outcomes
The world’s first clinical trial (SURGUVANT) evaluating anti-inflammatory use at the time of surgery in colon cancer patients to improve their cancer outcome has been published in scientific journal, BMC Cancer. The research successfully tested an anti-inflammatory agent with anti-cancer properties known as Taurolidine in the SURGUVANT trial which was funded by a grant from Geistlich Pharma AG, Wolhusen, Switzerland. […]
Continue reading »